Tate's most recent trade in Belden Inc was a trade of 219 Common Stock done at an average price of $96.6 . Disclosure was reported to the exchange on July 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Belden Inc | Leah Tate | SVP - HR | Other type of transaction at price $ 96.62 per share. | 10 Jul 2025 | 219 | 30,389 (0%) | 0% | 96.6 | 21,160 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 453 | 112,196 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 45 | 5,018 (0%) | 0% | 0 | Common Stock | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 2,132 | 24,707 (0%) | 0% | 0 | Common Stock Holding | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 1,126 | 1,126 | - | - | Restricted Share Units | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2025 | 1,006 | 2,012 | - | - | Restricted Share Units | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.75 per share. | 30 May 2025 | 204,954 | 645,556 | - | 90.8 | 18,599,760 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.06 per share. | 30 May 2025 | 156,288 | 850,510 | - | 90.1 | 14,076,047 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.05 per share. | 30 May 2025 | 92,200 | 1,006,798 | - | 89.0 | 8,210,272 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.14 per share. | 30 May 2025 | 19,998 | 1,098,998 | - | 88.1 | 1,762,708 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.04 per share. | 30 May 2025 | 15,492 | 630,064 | - | 92.0 | 1,425,831 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 94.33 per share. | 30 May 2025 | 7,100 | 618,996 | - | 94.3 | 669,729 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.96 per share. | 30 May 2025 | 3,968 | 626,096 | - | 93.0 | 368,861 | Common Stock |
| Healthstream Inc | Deborah Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 3,048 | 3,048 | - | - | Restricted Share Units | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.67 per share. | 16 May 2025 | 4,247 | 239,114 | - | 90.7 | 385,087 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.33 per share. | 16 May 2025 | 3,979 | 235,135 | - | 90.3 | 359,440 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.16 per share. | 16 May 2025 | 881 | 243,361 | - | 92.2 | 81,189 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.77 per share. | 13 May 2025 | 1,667 | 31,837 (0%) | 0% | 85.8 | 142,979 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 1,667 | 1,666 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 113.85 per share. | 13 May 2025 | 1,436 | 30,401 (0%) | 0% | 113.9 | 163,489 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 113.64 per share. | 13 May 2025 | 231 | 30,170 (0%) | 0% | 113.6 | 26,251 | Common Stock |
| JELD-WEN Holding Inc. | Bruce M. Taten | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 37,974 | 107,641 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 9,404 | 111,742 (0%) | 0% | 0 | Common Stock | |
| JELD-WEN Holding Inc. | Bruce M. Taten | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.34 per share. | 25 Apr 2025 | 3,576 | 69,667 (0%) | 0% | 5.3 | 19,096 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 419 | 102,338 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 51 | 4,972 (0%) | 0% | 0 | Common Stock | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 1,149 | 22,575 (0%) | 0% | 0 | Common Stock Holding | |
| Healthstream Inc | Deborah Tate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 1,149 | 0 | - | - | Restricted Share Units | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2025 | 125,800 | 1,118,996 | - | 0 | Common Stock | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 82.53 per share. | 26 Feb 2025 | 125,800 | 0 | - | 82.5 | 10,382,890 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2025 | 125,800 | 125,800 | - | 0 | Common Stock | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Feb 2025 | 125,800 | 1,244,796 | - | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 4,518 | 27,085 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 3,085 | 30,170 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 441 | 0 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.79 per share. | 21 Feb 2025 | 441 | 23,008 (0%) | 0% | 53.8 | 23,721 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 435 | 22,808 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 111.09 per share. | 21 Feb 2025 | 277 | 22,731 (0%) | 0% | 111.1 | 30,772 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 241 | 22,567 (0%) | 0% | 0 | Common Stock | |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 111.76 per share. | 21 Feb 2025 | 164 | 22,567 (0%) | 0% | 111.8 | 18,329 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 92.07 per share. | 18 Feb 2025 | 34,474 | 244,242 | - | 92.1 | 3,174,028 | Common Stock |
| Trustmark Corp. | Granville Tate | Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.67 per share. | 14 Feb 2025 | 1,100 | 54,383 (0%) | 0% | 37.7 | 41,437 | Common Stock |
| Dow | Jeffrey L. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 109,080 | 109,080 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Dow | Jeffrey L. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 17,650 | 97,370 (0%) | 0% | 0 | Common Stock | |
| Trustmark Corp. | Granville Tate | Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 3,957 | 55,483 (0%) | 0% | 0 | Common Stock | |
| Trustmark Corp. | Granville Tate | Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 6,927 | 53,681 (0%) | 0% | 0 | Common Stock | |
| Trustmark Corp. | Granville Tate | Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.57 per share. | 11 Feb 2025 | 2,155 | 51,526 (0%) | 0% | 38.6 | 83,118 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Sale of securities on an exchange or to another person at price $ 114.77 per share. | 07 Feb 2025 | 2,400 | 23,243 (0%) | 0% | 114.8 | 275,448 | Common Stock |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 382 | 101,919 (0%) | 0% | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 46 | 4,921 (0%) | 0% | 0 | Common Stock | |
| Astera Labs Inc. | Tate T. Michael | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2024 | 30,000 | 1,390,596 | - | 0 | Common Stock | |
| Astera Labs Inc. | Tate T. Michael | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2024 | 10,000 | 1,380,596 | - | 0 | Common Stock | |
| Astera Labs Inc. | T. Tate Michael | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Dec 2024 | 10,000 | 1,370,596 | - | 0 | Common Stock | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 119.67 per share. | 04 Dec 2024 | 4,353 | 1,413,571 | - | 119.7 | 520,922 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 115.44 per share. | 04 Dec 2024 | 3,622 | 1,425,266 | - | 115.4 | 418,135 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 117.68 per share. | 04 Dec 2024 | 2,840 | 1,420,526 | - | 117.7 | 334,222 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 118.44 per share. | 04 Dec 2024 | 2,602 | 1,417,924 | - | 118.4 | 308,178 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 116.66 per share. | 04 Dec 2024 | 1,900 | 1,423,366 | - | 116.7 | 221,657 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 120.58 per share. | 04 Dec 2024 | 683 | 1,412,888 | - | 120.6 | 82,359 | Common Stock |
| Trustmark Corp. | Tate Granville | Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 2,500 | 46,754 (0%) | 0% | 0 | Common Stock | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 103.49 per share. | 02 Dec 2024 | 84,220 | 1,599,588 | - | 103.5 | 8,715,919 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 102.59 per share. | 02 Dec 2024 | 55,003 | 1,683,808 | - | 102.6 | 5,642,576 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 112.53 per share. | 02 Dec 2024 | 27,905 | 1,517,980 | - | 112.5 | 3,140,250 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 115.71 per share. | 02 Dec 2024 | 25,978 | 1,453,709 | - | 115.7 | 3,006,034 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 101.62 per share. | 02 Dec 2024 | 24,077 | 1,738,811 | - | 101.6 | 2,446,753 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 116.46 per share. | 02 Dec 2024 | 23,222 | 1,430,487 | - | 116.5 | 2,704,395 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.52 per share. | 02 Dec 2024 | 21,670 | 1,565,678 | - | 110.5 | 2,395,072 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.54 per share. | 02 Dec 2024 | 19,804 | 1,479,687 | - | 114.5 | 2,268,315 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 111.32 per share. | 02 Dec 2024 | 19,793 | 1,545,885 | - | 111.3 | 2,203,274 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 113.54 per share. | 02 Dec 2024 | 18,489 | 1,499,491 | - | 113.5 | 2,099,291 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 109.58 per share. | 02 Dec 2024 | 4,575 | 1,587,348 | - | 109.6 | 501,343 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 104.44 per share. | 02 Dec 2024 | 3,700 | 1,595,888 | - | 104.4 | 386,429 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 107.08 per share. | 02 Dec 2024 | 1,600 | 1,593,103 | - | 107.1 | 171,320 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 117.10 per share. | 02 Dec 2024 | 1,599 | 1,428,888 | - | 117.1 | 187,243 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 105.80 per share. | 02 Dec 2024 | 1,185 | 1,594,703 | - | 105.8 | 125,374 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 108.16 per share. | 02 Dec 2024 | 1,180 | 1,591,923 | - | 108.2 | 127,627 | Common Stock |
| Dow | Jeffrey L. Tate | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 44.21 per share. | 29 Nov 2024 | 2,426 | 79,720 (0%) | 0% | 44.2 | 107,253 | Common Stock |
| Healthstream Inc | Deborah Tate | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Nov 2024 | 900 | 21,426 (0%) | 0% | 0 | Common Stock Holding | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.81 per share. | 18 Nov 2024 | 7,398 | 286,424 | - | 90.8 | 671,834 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 30.60 per share. | 14 Nov 2024 | 694 | 293,822 | - | 30.6 | 21,236 | Common Stock |
| Aviat Networks Inc | Bruce M. Taten | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2024 | 8,339 | 19,798 (0%) | 0% | 0 | Common Stock | |
| Aviat Networks Inc | Bruce M. Taten | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.39 per share. | 08 Nov 2024 | 1,619 | 18,179 (0%) | 0% | 14.4 | 23,297 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.11 per share. | 01 Nov 2024 | 1,748 | 25,985 (0%) | 0% | 45.1 | 78,852 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,748 | 0 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.77 per share. | 01 Nov 2024 | 1,667 | 27,002 (0%) | 0% | 85.8 | 142,979 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,667 | 3,333 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.14 per share. | 01 Nov 2024 | 1,528 | 25,157 (0%) | 0% | 51.1 | 78,142 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,528 | 0 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 115.89 per share. | 01 Nov 2024 | 1,359 | 25,643 (0%) | 0% | 115.9 | 157,490 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.79 per share. | 01 Nov 2024 | 1,163 | 24,406 (0%) | 0% | 61.8 | 71,862 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,163 | 0 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 115.89 per share. | 01 Nov 2024 | 987 | 24,998 (0%) | 0% | 115.9 | 114,380 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 115.89 per share. | 01 Nov 2024 | 920 | 24,237 (0%) | 0% | 115.9 | 106,616 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.79 per share. | 01 Nov 2024 | 884 | 25,882 (0%) | 0% | 53.8 | 47,550 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 884 | 441 | - | - | Stock Appreciation Rights | |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 115.89 per share. | 01 Nov 2024 | 777 | 23,629 (0%) | 0% | 115.9 | 90,044 | Common Stock |
| Belden Inc | Leah Tate | SVP - HR | Sale or transfer of securities back to the company at price $ 115.89 per share. | 01 Nov 2024 | 547 | 25,335 (0%) | 0% | 115.9 | 63,390 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.03 per share. | 09 Oct 2024 | 100,000 | 1,762,888 | - | 62.0 | 6,203,360 | Common Stock |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Oct 2024 | 1,033,780 | 293,128 | - | 0 | Common Stock | |
| Astera Labs Inc. | Michael T. Tate | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Oct 2024 | 1,033,780 | 1,862,888 | - | 0 | Common Stock | |
| Huntington Bancshares | Jeffrey L. Tate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 428 | 101,537 (0%) | 0% | 0 | Common Stock |